Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Advanced Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency; it inhibits endothelial cell migration and tube formation in vitro (IC₅₀ < 12 nM for all three targets) (Xie et al., 2018). Compared to sunitinib and sorafenib, anlotinib exhibits superior inhibitory effects on angiogenic signaling and tumor microvessel density in preclinical models (doi:10.1111/cas.13536). The compound shows good oral bioavailability, high plasma protein binding, and preferential tissue accumulation with minimal systemic toxicity in animal studies. APExBIO supplies Anlotinib (hydrochloride) (SKU C8688) for research use, supporting protocol optimization in cell-based angiogenesis assays (product page). This review provides mechanistic detail, benchmarking, and integration guidance for cancer and angiogenesis research workflows.

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis, enabling neoplastic tissues to obtain oxygen and nutrients. It is regulated by multiple signaling pathways, primarily those initiated by vascular endothelial growth factor (VEGF) and its receptors, especially VEGFR2 (Xie et al., 2018). Platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) signaling also contribute to endothelial cell proliferation and vessel formation. Targeting these receptor tyrosine kinases (RTKs) is a validated strategy for disrupting pathological angiogenesis in solid tumors. VEGFR2 inhibition, in particular, has been shown to significantly reduce tumor vascularization and growth in vivo. However, monotherapy with single-target agents is limited by compensatory signaling and acquired resistance. Thus, multi-targeted inhibitors like anlotinib are designed to simultaneously block VEGFR2, PDGFRβ, and FGFR1, suppressing both primary and redundant pro-angiogenic pathways for more sustained anti-tumor efficacy.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride acts as a potent multi-target tyrosine kinase inhibitor. It binds the ATP-binding pocket on VEGFR2, PDGFRβ, and FGFR1, preventing receptor autophosphorylation and downstream signaling (Xie et al., 2018). The compound inhibits VEGF/PDGF-BB/FGF-2 induced endothelial cell migration and capillary-like tube formation in a dose-dependent manner. Specific IC₅₀ values are 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1, as measured in enzyme assays at 25°C, pH 7.4, 60 min incubation (APExBIO). In cultured human vascular endothelial cells (EA.hy 926), anlotinib blocks activation of the ERK signaling pathway, leading to reduced cell proliferation and migration. Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates greater selectivity and potency against these pro-angiogenic RTKs. In vivo, oral dosing in mouse models results in decreased tumor microvessel density and, in some cases, tumor regression.

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 kinase activity with an IC₅₀ of 5.6 ± 1.2 nM under standard enzyme assay conditions (Xie et al., 2018).
• In endothelial cell-based capillary tube formation assays, anlotinib suppresses VEGF-induced tube formation at concentrations as low as 10 nM (doi:10.1111/cas.13536).
• Anlotinib demonstrates oral bioavailability of 28–58% in rats and 41–77% in dogs (single-dose pharmacokinetics at 25°C, fasting) (APExBIO).
• High plasma protein binding (93% in human plasma, equilibrium dialysis, pH 7.4) ensures extended systemic exposure (Xie et al., 2018).
• In mouse xenograft models, anlotinib (oral, 3–10 mg/kg/day, 21 days) reduces tumor microvessel density and can induce tumor regression when compared to sunitinib and sorafenib (doi:10.1111/cas.13536).
• Anlotinib is well tolerated in animal studies, with a 14-day oral LD₅₀ of 1735.9 mg/kg and only mild systemic toxicity observed at high doses (APExBIO).

For further exploration of its pharmacological depth and comparison with other TKIs, see "Anlotinib Hydrochloride: Unraveling Multi-Target Angiogenesis" (this article extends mechanistic analysis to pathway-level effects beyond standard assay outputs).

Applications, Limits & Misconceptions

Applications: Anlotinib hydrochloride is used primarily in research settings to study anti-angiogenic mechanisms in vitro and in vivo. In cell-based assays, the compound is applied to human vascular endothelial cells (e.g., EA.hy 926, HUVEC) to investigate inhibition of cell migration, tube formation, and proliferation via ERK pathway modulation (product info). It is also used in rodent tumor xenograft models to evaluate tumor vascularization and regression. Researchers employ anlotinib in comparative studies against other TKIs for evaluating potency, selectivity, and pharmacokinetics. For protocol optimization and troubleshooting in angiogenesis assays, APExBIO's C8688 kit provides reproducible performance benchmarks (Enhancing Tumor Angiogenesis Assays; this article clarifies integration and selectivity issues not addressed in the linked workflow guide).

Limits & Misconceptions: While anlotinib is highly effective in suppressing VEGF-, PDGF-, and FGF-driven angiogenesis, it does not directly inhibit tumor cell proliferation at nanomolar concentrations; micromolar levels are required for cytotoxic effects in cancer cell lines (Xie et al., 2018). The compound should not be used for diagnostic or therapeutic purposes outside of controlled research protocols. Its multi-target profile, though advantageous for redundancy, may complicate data interpretation where pathway-specific effects are required. Anlotinib's in vivo efficacy is context-dependent and may vary with tumor model, dosing, and the presence of compensatory angiogenic pathways.

Common Pitfalls or Misconceptions

• Not a cytotoxic agent at typical research concentrations: Anlotinib does not significantly inhibit tumor cell proliferation in vitro below micromolar concentrations (doi:10.1111/cas.13536).
• Not suitable for clinical or diagnostic use: Product is for research use only, as supplied by APExBIO (product page).
• Multi-target profile may confound pathway-specific analysis: Interpretation of results in pathway-focused studies requires careful controls.
• Ineffective against non-angiogenic or VEGF-independent tumors: Efficacy is reduced where tumor growth does not rely on angiogenesis.
• Pharmacokinetics may differ across species: Rodent data may not translate directly to human settings; always verify conditions.

Workflow Integration & Parameters

Anlotinib hydrochloride (SKU C8688) from APExBIO is supplied as a research-use-only reagent and should be stored at -20°C in a desiccated environment. For in vitro studies, stock solutions are typically prepared in DMSO and diluted into assay buffer (pH 7.4, 37°C) immediately prior to use. Recommended working concentrations range from 1 to 100 nM for endothelial cell migration and tube formation assays. In cell-based protocols, exposure time is usually 24–72 hours. For in vivo rodent studies, oral dosing regimens of 3–10 mg/kg/day have demonstrated efficacy in xenograft models. Pharmacokinetic studies indicate rapid oral absorption and extensive distribution, with high tissue concentrations measured in lung, liver, kidney, heart, and tumor. Data interpretation should account for high plasma protein binding and CYP3A-mediated metabolism. For detailed troubleshooting and reproducibility strategies, see Solving Lab Challenges with Anlotinib (hydrochloride); this article updates selectivity and dosing guidance with recent benchmarks not included in the linked resource.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, well-tolerated multi-target tyrosine kinase inhibitor for advanced angiogenesis research. Its nanomolar potency against VEGFR2, PDGFRβ, and FGFR1, in conjunction with favorable pharmacokinetic and safety profiles, makes it a valuable tool in tumor angiogenesis and signaling pathway studies. Supplied by APExBIO, the C8688 kit supports high-confidence, reproducible results in endothelial cell and tumor models. Ongoing research is extending its utility to combinatorial studies and resistance mechanism exploration. For ordering information or detailed technical support, refer to the Anlotinib (hydrochloride) product page.